(VIRP) Virbac - Ratings and Ratios

Virbac SA, a global leader in animal health, specializes in developing, manufacturing, and distributing a comprehensive range of products and services for companion and farm animals. With a strong presence across France, Europe, Latin America, North America, Asia, the Pacific, Africa, and the Middle East, Virbac is committed to innovation and sustainability in animal health. The company offers an extensive portfolio including vaccines, dental hygiene products, reproduction aids, dermatology solutions, parasiticides, diagnostics, antibiotics, aquaculture products, and veterinary medicines for anesthesia, geriatrics, behavior management, and injectable micronutrients. Additionally, Virbac provides petfood and electronic identification solutions. Serving veterinarians, farmers, and pet owners, Virbac has established itself as a key player in enhancing animal health and welfare. Founded in 1968, the company is headquartered in Carros, France.

Over the next three months, Virbac SAs stock is expected to experience a period of consolidation. Technically, the stock is currently trading above its 20-day and 50-day moving averages, indicating a short-term uptrend, while remaining below the 200-day moving average, suggesting a longer-term downtrend. The Average True Range (ATR) of 11.22 points to moderate volatility. Support is anticipated around the SMA 50 level of 303.22, with resistance near the SMA 200 at 331.44. Fundamentally, with a Return on Equity (RoE) of 20.70% and a Price-to-Book (P/B) ratio of 2.42, the stock is fairly valued, supported by strong earnings efficiency. The Price-to-Earnings (P/E) ratio of 17.66 aligns with industry standards, indicating reasonable valuation. Overall, the stock is expected to trade within a range bounded by these technical levels, with potential for testing the SMA 200 as resistance.